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Abstract
Background:  Human sex hormone-binding globulin (SHBG) regulates free sex steroid
concentrations in plasma and modulates rapid, membrane based steroid signaling. SHBG is encoded
by an eight exon-long transcript whose expression is regulated by a downstream promoter (PL).
The SHBG gene was previously shown to express a second major transcript of unknown function,
derived from an upstream promoter (PT), and two minor transcripts.
Results: We report that transcriptional expression of the human SHBG gene is far more complex
than previously described. PL and PT direct the expression of at least six independent transcripts
each, resulting from alternative splicing of exons 4, 5, 6, and/or 7. We mapped two transcriptional
start sites downstream of PL and PT, and present evidence for a third SHBG gene promoter (PN)
within the neighboring FXR2 gene; PN regulates the expression of at least seven independent SHBG
gene transcripts, each possessing a novel, 164-nt first exon (1N). Transcriptional expression
patterns were generated for human prostate, breast, testis, liver, and brain, and the LNCaP, MCF-
7, and HepG2 cell lines. Each expresses the SHBG transcript, albeit in varying abundance.
Alternative splicing was more pronounced in the cancer cell lines. PL- PT- and PN-derived
transcripts were most abundant in liver, testis, and prostate, respectively. Initial findings reveal the
existence of a smaller immunoreactive SHBG species in LNCaP, MCF-7, and HepG2 cells.
Conclusion: These results extend our understanding of human SHBG gene transcription, and
raise new and important questions regarding the role of novel alternatively spliced transcripts, their
function in hormonally responsive tissues including the breast and prostate, and the role that
aberrant SHBG gene expression may play in cancer.
Background
Sex Hormone-Binding Globulin (SHBG) is a multifunc-
tional protein that influences androgen and estrogen
action in humans on at least two levels. In plasma, SHBG
is the major sex steroid-binding protein, regulating their
availability to responsive tissues. SHBG is also an integral
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part of a membrane-based steroid signaling pathway in
certain responsive tissues, including the prostate and
breast.
The initial steps of SHBG-mediated steroid signaling in
the prostate and breast have been well characterized in
cultured cells and tissue explants [1,2]. Unliganded SHBG
binds to a specific membrane receptor (RSHBG); the SHBG-
RSHBG complex is activated by subsequent binding of an
appropriate androgen or estrogen, independently of the
androgen or estrogen receptors [3]. RSHBG activation leads
to a rapid increase in intracellular cAMP [4,5], presumably
through the action of a G protein [6]. Studies in cultured
cells have demonstrated downstream effects that include
protein kinase A activation [7], increased prostate specific
antigen expression [8], decreased progesterone receptor
expression [9], induced apoptosis [10], and seemingly dis-
parate findings of reduced MCF-7 breast cancer cell
growth [11-13] and increased ALVA-41 prostate cancer
cell growth [14]. However, a biologic role of RSHBG signal-
ing in the intact prostate and breast awaits demonstration.
The source of the SHBG that initializes RSHBG signaling in
vivo is unclear; it could be taken up from the plasma,
where it is relatively abundant, or synthesized in cells in
which signaling occurs. In addition to the liver which is
well known to be the source of plasma SHBG, and testis
(which synthesizes the differentially glycosylated SHBG
isoform, androgen binding protein (ABP), SHBG protein
and mRNA have been demonstrated in other human tis-
sues, including the prostate and breast [15-19]. The rela-
tively stable concentration of plasma SHBG [20] makes it
a less likely source for the initiation of RSHBG signaling, as
the physiology of important signaling molecules depends
on their variation with time. Other, more variable sources
of SHBG would be better candidates. This raises the possi-
bility that the prostate and breast themselves could con-
trol local SHBG concentrations, thereby regulating RSHBG
activation in an autocrine/paracrine manner.
Most work regarding human SHBG mRNA expression has
been based on earlier reports of the existence of two major
and two minor transcripts [21-26] (GenBank Accession
Number: M31651). A downstream promoter, (PL), regu-
lates the expression of a major, eight-exon mRNA tran-
script that encodes SHBG (NM_001040)(Figure 1). The
liver secretes SHBG [27]; the nascent SHBG translation
product is a 402 amino acid precursor protein which is
glycosylated and cleaved at its amino terminus to remove
a 29 amino acid long leader peptide [21,22,28] leading to
the secretion of mature SHBG into plasma. Domains
responsible for steroid binding and dimerization are
encoded within exons 3 and 4[29,30], while binding of
SHBG to RSHBG is mediated by a decapeptide sequence
encoded within exon 3 [31]. Mature SHBG has an O-
linked glycosylation site at Thr7, and N-linked sites at Asn
351 and Asn 367 [32,33]. The identical eight exon tran-
script is also expressed in the testis, which is translated
into ABP [23,25]. In addition to the SHBG/ABP transcript,
there is a second major SHBG gene transcript in the testis
(X16350, X16351) derived from a second promoter (PT),
located 1.9 kb upstream of PL [22]. It possesses unique 5'
end sequences, referred to here as exon 1T, and lacks exon
7. Transgenic mice express a human SHBG species that
appears to be attributable to this transcript [34], however,
such an isoform has not been identified in humans. In
addition to the two major transcripts, two minor human
SHBG gene transcripts resulting from alternative splicing
of exon 7 have been reported [35]. These include an
SHBG/ABP-like transcript that lacks exon 7 (Figure 1), and
an eight exon long transcript originating from PT that
retains exon 7.
The LNCaP (prostate cancer) and MCF-7 (breast cancer)
cell lines express SHBG at the mRNA and protein levels
and possess RSHBG activity[12,17-19], making them attrac-
tive in vitro models for studying the effects of local SHBG
expression on steroid signaling and RSHBG  regulation.
These cell lines retain both alleles of the p53 gene [36],
located ~35 kb from the distal end of the SHBG gene locus
on chromosome 17p13.1 and, due to this extremely close
linkage, we presumed that both SHBG alleles also remain
intact. We initially intended to confirm prior reports of
SHBG mRNA expression in these cell lines as a prelude to
investigating the function of locally expressed SHBG in
the prostate and breast. As positive controls for SHBG
mRNA expression, we included the human HepG2
(hepatoma) cell line (known to express abundant
amounts of the SHBG/ABP transcript) and normal testis
tissue (known to express abundant amounts of the major
PT-derived transcript).
In the course of that effort, we found that transcription of
the human SHBG gene is far more complex than had been
previously reported. We performed a detailed structural
analysis of human SHBG transcripts from the human
LNCaP, MCF-7, and HepG2 cell lines, and from normal
human liver, testis, prostate, breast, and brain tissues. RT-
PCR based mapping assays revealed the existence of at
least three distinct human SHBG gene promoters; we
determined transcriptional start sites for each. In addition
to the four previously reported transcripts, we identified
and characterized 15 novel SHBG gene transcripts result-
ing from alternate splicing of exons 4, 5, 6, and/or 7. Real-
time, quantitative PCR showed that SHBG transcription is
tissue dependent, and perhaps, cancer dependent. We also
detected a smaller sized immunoreactive SHBG species in
LNCaP, MCF-7 and HepG2 cells, which raises the possi-
bility that at least one of these transcripts is translated.
Based on our current knowledge of SHBG function, theseBMC Molecular Biology 2009, 10:37 http://www.biomedcentral.com/1471-2199/10/37
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results could have important biologic implications for the
modulation of RSHBG activity and cellular steroid signal-
ing.
Results
SHBG exon 5–8 RT-PCR
Because the longest run of A residues within the human
SHBG coding region is only three, an oligo-d(T) primer
was selected for first strand cDNA synthesis from LNCaP,
MCF-7 and HepG2 cells, and from normal testis. As a con-
trol for the initial SHBG RT-PCR assays, first strand cDNA
was also synthesized from MCF-7-Tr, a stably transfected
cell line that constitutively overexpresses relatively high
amounts of the contiguous exon 1L-8 transcript contain-
ing the human SHBG/ABP coding region.
A short SHBG RT-PCR assay, spanning exons 5 through 8
[17], was used to generate partial SHBG mRNA expression
profiles for LNCaP, MCF-7, HepG2, testis and the MCF-7-
Tr control. Based upon prior reports of SHBG transcrip-
tion (see Introduction), two RT-PCR fragments were antic-
ipated from LNCaP and MCF-7 cells, a contiguous 521-bp
fragment that retains exon 7, and a smaller 313-bp frag-
ment that lacks exon 7. Instead, LNCaP and MCF-7 gave
rise to three distinct RT-PCR fragments (Figure 2A). All
521-bp, 313-bp, and 176-bp RT-PCR bands were isolated,
reamplified, and sequenced. In addition to the expected
521-bp and 313-bp RT-PCR fragments, whose identities
were confirmed by sequencing, we also found a 176-bp
RT-PCR fragment of low abundance. The 176-bp fragment
was derived from a transcript(s) in which exon 5 is directly
spliced to exon 8 (sequence analysis). This same 176-bp
fragment was generated from HepG2 and normal testis.
HepG2 and normal testis RT-PCR also revealed a faint,
intermediate RT-PCR fragment of approximately 384-bp.
We were unable to reamplify this fragment and its iden-
tity, therefore, is not established. As expected, the MCF-7-
Tr RT-PCR control gave rise only to the contiguous 521-bp
Schematic diagram of the contiguous human SHBG/ABP transcript and alternatively spliced transcripts arising from the down- stream promoter, PL Figure 1
Schematic diagram of the contiguous human SHBG/ABP transcript and alternatively spliced transcripts aris-
ing from the downstream promoter, PL. A structure/function diagram for the eight exon long SHBG/ABP transcript is 
shown above. The nucleotide positions of each exon are at the top (the exon 1 start codon defined as beginning with nucle-
otide +1); below that, the number of amino acids encoded by each exon. Conserved exons are numbered in white, alterna-
tively spliced exons in yellow. Exon boundaries are denoted by horizontal white rectangles. Shown in red is the region of the 
SHBG/ABP transcript encoding the 29 amino acid long signal peptide, in light blue, the 383 amino acid long SHBG/ABP mono-
mer. Steroid binding determinants in the mature SHBG protein are denoted by black rectangles, those forming the dimeriza-
tion domain are blue, and that encoding the decapeptide sequence known to mediate binding of SHBG to RSHBG is purple. 
Below, in black, are linear depictions of the two previously described human SHBG gene transcripts originating from PL; the 
four novel transcripts described in this study are depicted in grey. Transcripts are identified on the left by missing exons. Three 
of five alternatively spliced PL transcripts retain the SHBG/ABP reading frame, whereas those lacking exon 7 alone and exons 
4–7 undergo identical frameshifts within exon 8 that may affect their inherent stabilities (see discussion).
nt 1-117 
(39aa)
nt 118-209 
(30aa+2nt)
nt 210-399
( 63aa+1nt)
nt 400-558 
(53aa)
nt 559-718 
(53aa+1nt)
nt 719-855
(45aa+2nt)
nt 856-1063
(69a+1nt)
nt 1064-1206
(47aa+2nt)
1L 2 3 45 67 8 exon
Red: SHBG signal peptide, cleaved prior to secretion- amino acids -29 to -1 
Purple: Decapeptide sequence shown to bind to the SHBG receptor (RSHBG)- amino acids 48-57
Blue: SHBG dimerization domain- amino acids 72-77; 84-93; 119-126; 154-155
Black: Steroid binding domain determinants- amino acids 42; 65; 128-134
-29 -11 373
SHBG/ABP
- exon 7
- exons 6,7
- exons 4,7
- exons 4,6,7
- exons 4,5,6,7
Gycosylation sites- Thr7 (O-linked); Asn351, Asn367 (N-linked) BMC Molecular Biology 2009, 10:37 http://www.biomedcentral.com/1471-2199/10/37
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Short range RT-PCR assays for human SHBG gene expression Figure 2
Short range RT-PCR assays for human SHBG gene expression. A. SHBG exon 5–8 assay. First strand cDNAs were 
generated from MCF-7, MCF-7-Tr LNCaP, HepG2 cells and normal human testis tissue using an oligo dT primer (see meth-
ods). Three RT-PCR transcripts were generated in the MCF-7 and LNCaP lanes, and four in the HepG2 and testis lanes. MCF-
7-Tr is an MCF-7 clone stably transfected with a plasmid constitutively expressing large amounts of SHBGL. All bands were 
reamplified and sequenced. SHBG RT-PCR transcript structures are given on the right. Note- this is a merged figure- the DNA 
marker and transfection control lanes were consolidated from a different part of the gel. B. SHBG exon 2–8 assay. PCR prim-
ers, specific for exon 2 and exon 8, were used to amplify cDNAs prepared from HepG2, LNCaP, MCF-7, MCF-7-Tr, and nor-
mal human testis, liver, prostate, breast, and brain tissues. All bands from HepG2, LNCaP, MCF-7, and testis were reamplified 
and sequenced. Bands labeled "*" produced sequences that were inconsistent with the sizes of the transcripts, and which were 
identical to other characterized sequences. DNA marker sizes, in base pairs, are given on the left. RT-PCR fragment transcript 
structures and sizes are given on the right. Note- this is a merged figure- the transfection control lane was taken from a differ-
ent part of the gel.
 A. 
 B.
517/506
396
1018 
-actinBMC Molecular Biology 2009, 10:37 http://www.biomedcentral.com/1471-2199/10/37
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fragment, undoubtedly because the highly overexpressed
full-length SHBG/ABP cDNA transcript overwhelmed the
RT-PCR assay. The relative intensities of the 521-bp and
313-bp bands varied dependent on the source of the RNA.
(Figure 2A).
SHBG exon 2–8 RT-PCR
An exon 2–8 RT-PCR assay was designed to screen for
alternative splicing of downstream exons, 3–7, in a single
reaction, intentionally bypassing the assessment of indi-
vidual contributions from PL and PT. First strand cDNAs,
generated from normal liver, prostate, and breast, as well
as from brain (which expresses SHBG [37-39], were also
included as templates for RT-PCR. Adding further com-
plexity to the picture of SHBG gene expression, the exon
2–8 RT-PCR assay generated nine distinct RT-PCR frag-
ments (Figure 2B; summarized in Figure 3). Each HepG2,
liver and testis RT-PCR fragment was reamplified and
sequenced. The largest fragment, 1075-bp, contained the
expected contiguous exon 2–8 sequence. Four of the
Summary of RT-PCR results Figure 3
Summary of RT-PCR results. Semiquantitative representation of the relative amounts of each RT-PCR fragment. For ease 
of comparison, the abundance of each RT-PCR fragment in the exon 2–8 and the exon 1–8 RT-PCR assays has been assigned a 
value, denoted by the following- "+++++" most abundant, down to "+" detectable, "+/-" barely detectable, and "-" not detecta-
ble. For each individual assay, transcript structures were determined by sequence analysis of designated RT-PCR fragments 
(see Results). These were used to assign structures to similar sized RT-PCR fragments from remaining samples. *: This band 
was a mixture of 1N-8-exon 4 sequences and those of an ambiguous sequence. "?"-inconsistent appearance of fragment, pre-
sumably due to low abundance.
30
RT-PCR ASSAY  HepG2  LNCaP  MCF-7  Testis  Liver  Prostate  Breast  Brain 
Exon 2-8 
  RT-PCR Fragment                    
Structure size 
 Exons  2-8 1075 ++ +++ ++ ++  +++++  ++  ++  +++ 
 -  Exon 7 867 +++ ++  + +++  ++  +  +  ++ 
  - Exons 6,7  730 ++ ++ + +/-  +/- ++  +/-  ++ 
  - Exons 4,7  705 + +/-  +/-  +/-  -  +  -  - 
  - Exons 4,6,7  568 + + + - -  +  +  + 
RT-PCR ASSAY  HepG2 LNCaP MCF-7 Testis Liver  Prostate  Breast  Brain 
Exon 1L-8                   
Assession Number  RT-PCR Fragment                   
Structure size                 
NM_001040 Exons 1L-8 (SHBG/ABP)  1130 ++ ++ ++  +++  +++++  +  +  + 
- Exon 7  922 +++ +  + ++  ++  -  -  - 
EU352661 - Exons 6,7  785 ++ +  - + +  -  -  - 
EU352662 - Exons 4,7  760 ++ -  - - -  -  -  - 
EU352663 - Exons 4,6,7  623 ++ -  - - +  -  -  - 
EU352664 - Exons 4,5,6,7  463 +/- -  - +  +/- -  -  - 
RT-PCR ASSAY  HepG2 LNCaP MCF-7 Testis Liver  Prostate  Breast  Brain 
Exon 1T-8                   
 RT-PCR  Fragment                   
Structure size                 
EU352665 Exons 1T-8  1151 +/- ++ + ++  ++  +  +  ++ 
X16351 - Exon 7  943 +/- ++ +  +++++ +  -  -  + 
EU352666 - Exons 6,7  806 - ++  + - + +/-  +  ++ 
EU352667 - Exons 4,7  781 +/- +/- +/-  ++ -  -  -  - 
EU352668 - Exons 4,6,7  644 +/- + +  - -  -  -  - 
EU352669 - Exons 4,5,6,7  484 - +/-  +/-  - -  -  -  - 
RT-PCR ASSAY  HepG2 LNCaP MCF-7 Testis Liver  Prostate  Breast  Brain 
Exon 1N-8                   
RT-PCR Fragment                   
Structure size                 
EU352670 Exons 1N-8  1146 +/-? +++ ++ +/-?  -  +/-?  -  - 
EU352675 - Exon 4*   984 - ++  + - -  -  -  - 
EU352671 - Exon 7  938 +/-? +  +  -  -  -  -  - 
EU352672 - Exons 6,7  801 - +/-  +?  - -  -  -  - 
EU352676 - Exons 4,7  776 - ++  +?  - -  -  -  - 
EU352673 - Exons 4,6,7  639 - +  +/-  -  -  -  -  - 
479 EU352674 - Exons 4,5,6,7  -  +/-  -  -  -  -  -  - BMC Molecular Biology 2009, 10:37 http://www.biomedcentral.com/1471-2199/10/37
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remaining eight RT-PCR fragments were comprised of
sequences that were consistent with their sizes. From larg-
est to smallest, these transcripts lacked exon 7 (867-bp);
exons 6 and 7 (730-bp); exons 4 and 7 (705-bp); and
exons 4, 6 and 7 (568-bp). That exon 4 undergoes alterna-
tive splicing was confirmed using an RT-PCR assay that
spanned exons 3 and 5 (data not shown). A prior report
similarly found alternative splicing of exon 4, using an RT-
PCR assay that included primers specific for exons 3 and
7 [40]. For reasons that are unclear, the four remaining
RT-PCR fragments consistently gave sequences that were
identical to those described above. For example, we had
expected the ~913-bp RT-PCR fragment to give rise to a
sequence derived from a transcript lacking exon 4, how-
ever, it gave the 1L-8 sequence lacking exon 7. As
described below, given our positive identification of an
exon 1N-8 transcript lacking exon 4, we suspect that tech-
nical factors (perhaps the generation of single stranded
species during the PCR process) may have interfered with
our ability to positively detect this specific transcript in the
2–8, 1L-8 and 1T-8 RT-PCR assays. As expected, only a sin-
gle, intense contiguous exon 2–8 RT-PCR fragment was
generated from MCF-7-Tr. The same individual exon 2–8
RT-PCR fragments were generated from all three cell lines,
albeit in unequal abundances (Figure 2B).
Identification of a novel SHBG promoter and 
transcriptional start sites by RACE analysis
Before assessing the splicing patterns of full-length SHBG
transcripts, we used a nonbiased approach to determine
whether additional human SHBG gene promoters exist
along with PL and PT. In the rat, an alternative upstream
SHBG promoter, PA, appears to share promoter elements
with the rat FXR2 gene promoter [41]; it was speculated to
have an active human homologue [42].
Transcriptional start sites downstream of SHBG gene pro-
moters were identified using RLM-RACE ("RNA Ligase
Mediated-Rapid Amplification of cDNA Ends"), a modi-
fied RACE assay which included steps specifically
designed to prime only full length transcripts that possess
5' end cap structures. Beginning with total cellular RNAs
isolated from LNCaP, HepG2, and normal testis, multiple
RLM-RACE bands were generated from each sample (data
not shown), and each band was reamplified and
sequenced. The largest HepG2 band was actually a mix-
ture of two closely sized RACE fragments. Distinct exon 1L
5' end boundaries mapped to A residues respectively
located 79- (EU352659) and 38-nt (EU352660) upstream
of the ATG start codon, indicating that PL utilizes at least
two transcriptional initiation sites (Figure 4A). The proxi-
mal initiation site is consistent with positions of the major
exon 1L rat and rabbit SHBG transcriptional initiation
sites [41,43,44]. Our results differ from those human exon
1L transcriptional start sites originally determined [22],
and with those mapped in the liver and kidney of mice
expressing a human SHBG transgene [45].
The largest RLM-RACE band from normal testis was also a
mixture of two similarly sized fragments, both of which
contained exon 1T sequences (Figure 4B). The longer
sequence extended to a G residue located 183-nt upstream
of the exon 1T splice donor site (EU352657), whereas the
shorter fragment extended to a T residue located 161-nt
upstream (EU352658) of the splice donor site. These
results are consistent with primer extension studies in the
testis of a mouse expressing a human SHBG transgene,
where major exon 1T initiation sites were located 161,
169, and 186-nt upstream of the exon 1T splice donor site
[45]. Our results confirm that exon 1T lacks a potential
ATG start codon.
LNCaP gave rise to a RACE fragment consisting of a novel,
164-bp sequence (EU352656) spliced directly to SHBG
exon 2. This sequence maps to an uninterrupted genomic
locus located 17 kb upstream of PL  on chromosome
17p13.1, within the first intron of the fragile X mental
retardation-related 2 (FXR2, NM_004860) gene, and is
referred to here as SHBG exon 1N (Figure 5A). Exon 1N is
distinct from the human counterpart of rat exon 1A (Fig-
ure 5B) (AF044263), located on the opposite side of the
FXR2 gene promoter. We confirmed the 1N transcript ini-
tiation site in LNCaP cells in a second RACE assay, using
a downstream primer complementary to 3' end sequences
within exon 1N and the same 5' adaptor based primer
(data not shown). A short exon 1N-2 RT-PCR assay was
also performed on LNCaP, MCF-7, and HepG2 to confirm
that exon 1N is incorporated into mature SHBG mRNA
transcripts. A single RT-PCR fragment of the expected size
was generated from LNCaP and MCF-7, but not from
HepG2 (data not shown). All other RACE bands gener-
ated from LNCaP, HepG2 and normal testis were either
comprised of SHBG sequences that had recombined with
sequences from other chromosomes or were not specific
for SHBG, and were considered to be experimental arti-
facts. This experimental approach does not rule out the
possibility that additional human SHBG gene promoters
may still exist.
SHBG exon 1L-, 1T-, and 1N-8 RT-PCR
A comprehensive structural analysis of human SHBG gene
transcripts was performed using exon 1L-8, 1T-8, and 1N-
8 RT-PCR assays. These incorporated upstream primers
specific for either exons 1L, 1T, or 1N and a common,
downstream exon 8 primer. For these RT-PCR experi-
ments, because exon 8 is the last described exon in the
human SHBG gene, and it contains appropriate transcrip-
tional processing sequences, the use of a reverse primer
complementary to exon 8 sequences demonstrates the
likely presence of full length transcripts. For the most part,BMC Molecular Biology 2009, 10:37 http://www.biomedcentral.com/1471-2199/10/37
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counterparts of all exon 2–8 assay RT-PCR fragments
appeared in one or more of the exon 1–8 assays (Figure 6;
summarized in Figure 3). Overall, normal liver, prostate,
and breast expressed a lower proportion of alternatively
spliced SHBG transcripts than did the HepG2, LNCaP,
and MCF-7 cell lines.
Nine individual RT-PCR fragments were produced in the
exon 1L-8 assay (Figure 6A). Those generated from HepG2
were sequenced, as were all the 1130 bp fragments. The
sizes of six of the nine HepG2 fragments were consistent
with their sequences, whereas three were not, and remain
unattributable. Sequence analysis of all 1130-bp frag-
ments confirmed that they were derived from the contig-
uous SHBG/ABP transcript. This fragment was the sole
detectable 1L-8 species in prostate, breast and brain.
HepG2 also displayed 1L-8 RT-PCR fragments corre-
sponding to smaller sized, alternatively spliced transcripts
(Figure 1) that lacked exon 7, exons 4 and 7 (EU352662),
exons 6 and 7 (EU352661), exons 4, 6, and 7
(EU352663), and a novel, 463-bp RT-PCR fragment. The
463-bp fragment was comprised of exon 1L, 2, 3, and 8
sequences (EU352664), representing a transcript lacking
exons 4–7. To our knowledge, this is the first account of a
human SHBG transcript that lacks exon 5 sequences.
Alternatively spliced 1L-8 species were also observed in
liver, testis, MCF-7 and LNCaP (sequence analysis con-
firmed that the relatively abundant 922 bp fragment in
testis and liver corresponded to the transcript lacking exon
7). The sequences obtained for the remaining three differ-
ent sized RT-PCR fragments unexpectedly gave sequences
that were identical to specific SHBG transcripts described
Configuration of A) human SHBG exon 1L and B) exon 1T Figure 4
Configuration of A) human SHBG exon 1L and B) exon 1T. Transcriptional start sites, as determined in this study, are 
in bold letters and are denoted by a "≥ ". For both exons, position +1 is assigned to the distal, upstream start site. The exon 1L 
proximal start site is at position +42, the exon 1T proximal start site is at position +23. Upstream sequences are in italics. Pre-
viously reported human transcriptional start sites are underlined; not shown are two additional exon 1L start sites mapped at 
positions -114 and -125 [22]. Transcriptional start sites mapped in transgenic mice are in lower case letters [23]. "r" and "b" 
denote the corresponding positions of the major exon 1L rat [43] and rabbit [44] transcriptional start sites, respectively.
A.  Exon 1L 
     -50                         -1     
GTGCCCCTGTTTCCTTTACCCCCTCCTCCCCGGGCAACCTTTaaCCCTCC
     +1  >                     >rb  50     
ACCGCCCACACGCAAGGCTgCCTGCCTCTACACATTCTCCCAAGAGTTGT
      51        M e t 100
 CTGAGCCGCCGAGTGGACAGTGGCTGATTATGGAGAGCAGAGGCCCACTG
     101          150
 GCTACCTCGCGCCTGCTGCTGTTGCTGCTGTTGCTACTACTGCGTCACAC 
     151          190
  CCGCCAGGGATGGGCCCTGAGACCTGTTCTCCCCACCCAG 
B.  Exon 1T 
    -101                        -51     
TCGAATTCTGTCGCAGCAGGGGGCACAACTGTCAGCCAATCAGCTTGGAGA
     -50                         -1     
ACAGGCACGGCCGCGTCCCCCCCAAGCCCCACCCCCGACAGCTGGATcTT
     +1  >     >       50     
GTGACTGGGCTCCTgGGTAGAGtTCAAGGTTGGAGTGAAGCGGCTTCCTT
      51          100
GCGGTTGTGTGGGTGTCCCAACCTGGGTCGAGATACCCCGCGGTTCAAAG
     101          150 
  GCTCCCCCGCAGTGCTTTTTAAATTGACATATGCAGTGATAACCTGCTTT 
     151               183 
AGCCTCAGGCTCACTCACCCGCCCAGACCCTGGBMC Molecular Biology 2009, 10:37 http://www.biomedcentral.com/1471-2199/10/37
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A- Sequence of human SHBG exon 1N and species alignment Figure 5
A- Sequence of human SHBG exon 1N and species alignment. Shown is an alignment between the full human SHBG 
exon 1N sequence and homologous sequences from mouse, rat, rabbit and dog obtained from Genbank. The putative human 
ATG start codon is in bold and underlined. The TGA stop codon is in bold and italics. Conserved nucleotides between species 
are capitalized, differences are in lower case letters. The human exon 1N open reading frame is predicted to be only 3 amino 
acids long. B- Sequence of rat SHBG exon 1A and species alignment. Shown is an alignment between the rat SHBG exon 1A 
sequence and homologous human and mouse sequences obtained from Genbank. The putative rat ATG start codon is in bold 
and underlined. Conserved nucleotides between species are capitalized, differences are in lower case letters.
A.
Human  ATAAGA-TGAAAGTGGGGTGAGTGT-TCCAGAGCCAGTAGGC--AGAGGCCTCT
Mouse  tTAAGAccaAAAGTtGaGcaAaTGg-TCtAGAGCCAGTAGGC--AGAaGgCTCc
Rat   gTAAGA-TGAAAGTtGaGcaAaTGgtTCtAGAGCCAGTAGGCaaAGAaGCCTCc
Rabbit ATAAGg-cGAAAGTGGGGTGAGcGT-TCCAGAGCCAGTAGGC—-AGAGGCCTCT
Dog AcAgcA-gGAAAGTGGGGTGAGTcc-TgCAGAGCCAGgAGGC—-AGAGGCCTCT
Human  CTGAGGAAGATGAAAGGATCTTTTACGGGACAGAGGGCCTTCCCAAA-GGGACC 
Mouse  CT---------GAA--GAcCTaaTgtGGGACAGtGGaCCTTCCCAAg-GGGgtC 
Rat   CTGAaGA--ccGAA--GAcCTaaTAtGGcACAGtGGaCCTTCaCAAg-GGGgtC 
Rabbit CTGAGG---AT-AAAGGAgCTaaTAtGGGACAGAGGGCCTTCCCAAg-GGGgtC
Dog   CgGAGGAAGATaAAAGGATCTaaTAtGGGAC---GG-CCTTCCCAAgaGGG-ta
Human  GTGT-GG--AAGAAAGACAATTCTCCATGTGCTTGGATCGTG------GGGAAG 
Mouse aTGTaGGaaAAGAAtGcgAATcCTCCATGTGCTTGGgctGca------GGGgtG
Rat   aTGTaGGaaAAGAAAGggAATcCTCCATGTGCTTGGcT-GTa------GGGgAG 
Rabbit aTGTgGGagAAGAAA-AgAATTgTCCATGTGCTTGGAcCGcG------GGGAAG 
Dog   aTaggGaggAAtAAAGAgAATTCTCCATGTGCTTGGAcCGTGcggggtGGGggG 
Human  ATGTGATTAAGGTCTA 
Mouse  ATGTGATTAAaagCTg 
Rat   ATGTGATTAAaagCTg 
Rabbit AgGTGATTAAaGgCTA 
Dog   ATGTGATgAAGGTtTA
B.
Rat   CTTCCACATTCTCTTGCACTCTCTCACGCCCCCTCCTGGTCGCGTCTCTG 
Mouse  CTTCCACATTCTCTTGCACTCTCTCACGCCCCCTCCTGGTCGCcTCTCTG 
Human  CTTCCACATTCTCTTtCACTCTCTCACtCCCCCTCCTGGTCGCtTgctaG 
Rat   CGCTTGCGCAGAACGAGATGAGCGCTCTATCTGTACCGCTCCAACCTTCC
Mouse  CGCTTGCGCAGAACGAGgcGAaCGCTC--TCTGTACCaCTCCAACCTTCC
Human  CGCTTGCGCAGAACaAGATtAGCctTCTtTCTtcACCGCTCCA-CCgcCC
Rat   ACTGTCCCTGTCCCTTCCTTTCCCCGCCCCACAACACTGGAAGCAAACCA 
Mouse  ACTGTCCCTGTCCCTTCCTTTCCCCGCCCCACAACACTGGAAGCAAACCA 
Human  AgccaCCCcGTCtCTTCCTTTCCCCGCCCCACAACACTGagAaCcAACCA 
Rat   ATCAAGGGAAGAGAGGGGCCGCGCTCGCTCCGTCGGATTGGACTTCCGCC 
Mouse  ATCAAaGGgAGAGgGGGGCCGCGCTGCATCaGTCGGATTGGACTTCCGCC 
Human  ATCAgGGGgAGgGAGGGGCCGgGCTGCAcaCGTCcGATTGGgCg---GCg 
Rat   TCCACAAAGTGA 
Mouse  TCCACAAAGTGA 
Human   TCCgCAcAGTGA BMC Molecular Biology 2009, 10:37 http://www.biomedcentral.com/1471-2199/10/37
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RT-PCR analysis of transcripts including exon 1L (top), exon 1T (middle), and exon 1N (bottom) Figure 6
RT-PCR analysis of transcripts including exon 1L (top), exon 1T (middle), and exon 1N (bottom). Separate indi-
vidual RT-PCR amplifications were performed using 5' primers specific for exon 1L, 1T, and 1N, and a common exon 8 3' 
primer. Products were electrophoresed through a 1% agarose gel. All fragments were reamplified and sequenced. Bands 
labeled "*" produced ambiguous sequences that were inconsistent with the sizes of the transcripts, and which were identical to 
other characterized sequences (the smallest "*" fragment in the 1T-8 assay gave an unrelated sequence). DNA marker sizes, in 
base pairs, are given on the left. RT-PCR fragment transcript structures and sizes are given on the right. Note- 5A is a merged 
figure from two experiments to more clearly show the prostate 1L-8 RT-PCR fragment. Certain HepG2, MCF-7, testis and 
prostate fragments showed varied appearance in the 1N-8 assay, presumably due to their low relative abundance (Figure 3).
A.
B.
C.
36BMC Molecular Biology 2009, 10:37 http://www.biomedcentral.com/1471-2199/10/37
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above. Because of the incongruence of their sizes and
sequences, and despite repeated attempts at their resolu-
tion, their significance remains uncertain.
The exon 1T-8 assay produced a total of ten individual RT-
PCR fragments (Figure 6B). Those generated from LNCaP
and testis were reamplified and sequenced, as were all of
the 1152 bp fragments. Six of the ten fragments LNCaP
and testis fragments gave sequences that corresponded
with their sizes. As expected, the 943-bp fragment, corre-
sponding to the major exon 1T-8 transcript lacking exon
7, was the most abundant testis transcript. This transcript
was found in all samples other than for prostate and
breast. The contiguous exon 1T-8 transcript (EU352665)
was present in all samples tested. Alternatively spliced
exon 1T-8 transcripts lacking exons 6 and 7 (EU352666),
4 and 7 (EU352667), and 4, 6, and 7 (EU352668) were
also detected. Testis and liver generated a very weak 484-
bp 1T-8 fragment that was found by sequence analysis to
consist only of exons 1T, 2, 3, and 8 (EU352669). Of the
four remaining 1T-8 RT-PCR fragments, the smallest was
unrelated to any SHBG transcript, while the remaining
three fragments gave previously characterized SHBG tran-
script sequences that were incongruent with their sizes.
Sequence analysis confirmed that all 1152 bp fragments
from the remaining samples corresponded to the contigu-
ous 1T-8 transcript. Furthermore, the sequences of
selected abundant bands from the 1T-8 assay (the 806 bp
liver and brain, the 622 bp MCF-7, the 484 bp MCF-7),
also confirmed their structures.
The exon 1N-8 assay produced a total of nine individual
RT-PCR fragments (Figure 6C). RT-PCR fragments from
LNCaP and MCF-7 were reamplified and sequenced. Six
of the nine fragments gave sequences that corresponded
with their sizes. The contiguous 1146-bp 1N-8 fragment
(EU352670) was present in LNCaP and MCF-7, and was
faint in testis and prostate. The third largest fragment was
found to consist of a mixed sequence derived from two
transcripts, an appropriately sized 984-bp fragment that
had undergone splicing of exon 4 alone (EU352675) and
an aberrantly migrating fragment that lacks only exon 7.
This result suggests that transcripts lacking exon 4 may
have gone undetected in the 1L-8 and 1T-8 assays if their
sequence signals were drowned out by more abundant co-
migrating species. The 1N-8 assay also generated appro-
priately sized fragments corresponding to transcripts that
have undergone splicing of exon 7 (EU352671), and
exons 6 and 7 (EU352672), 4 and 7 (EU352676), 4, 6,
and 7 (EU352673), and exons 4, 5, 6, and 7 (EU352674)
(the latter did not reproduce well in Figure 6C). The repro-
ducibility of the testis and HepG2 assays was inconsistent,
likely due to the low abundance of 1N-8 transcripts in
these samples.
Quantitative PCR (qPCR) analysis of SHBG transcript 
abundance in human tissues and cell lines (Figure 7)
Four independent real time, qPCR assays were performed
to determine total relative SHBG mRNA abundance, and
the relative abundance of transcripts derived from each of
the three promoters. Total SHBG transcript abundance
was measured by targeting common sequences within
exons 2 and 3 that are present within all the SHBG tran-
scripts identified in this study. Contributions from indi-
vidual promoters were measured using qPCR assays
specific for exons 1L, 1T, and 1N, respectively. The sam-
ples were normalized against GAPDH expression.
Overall, the exon 1L, and 1T, qPCR assays gave results that
were comparable to the three individual exon 1–8 RT-PCR
assays. Among the normal tissues, overall SHBG gene
transcription, as measured by the exon 2–3 qPCR assay,
was highest in liver and testis. Transcripts containing exon
1L were most abundant in liver, whereas those containing
exon 1T were most abundant in testis. All normal tissues,
other than liver, expressed transcripts containing exon 1N.
Compared to their respective parental tissues, the three
cancer cell lines all displayed reduced expression of exon
1L-containing transcripts, whereas there were varied dif-
ferences in the abundance of exon 1T- and 1N-containing
transcripts. Apparent discrepancies between certain exon
1N qPCR and RT-PCR results could signify that novel 3'
end sequences may be incorporated into a fraction of
SHBG gene transcripts; this would have gone undetected
here due to our exclusive use of an exon 8-based down-
stream primer in longer range RT-PCR assays. Thus, actual
human SHBG gene expression may be even more complex
than is presented here.
Initial Western blot analysis of SHBG protein expression in 
HepG2, LNCaP, and MCF-7 cells
We addressed the question of the existence of SHBG iso-
forms in HepG2, LNCaP, and MCF-7 cells in initial West-
ern blot studies. Immunoblot analysis of solubilized
cellular proteins separated by SDS-PAGE, was performed
using a polyclonal rabbit anti-human SHBG antibody
(WAK-S1012-53, WAK-Chemie, Germany). Western blot
analysis (Figure 8) shows that all three cell lines express an
immunoreactive protein of the same molecular weight as
purified SHBG. A lower molecular weight species of 33–
35 kD was also detected (it could be greater because the
molecular weight marker appears to have run slower than
expected). To our knowledge, this is the first demonstra-
tion that such a lower molecular weight SHBG species
exists in these cell lines. Since immunoreactive SHBG was
not detected in the fetal bovine serum used in the pre-
pared media (data not shown), we believe that this lower
molecular weight species is either an isoform derived
from one of the alternatively spliced SHBG transcripts, orBMC Molecular Biology 2009, 10:37 http://www.biomedcentral.com/1471-2199/10/37
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a proteolytic fragment of SHBG itself. Assigning one of the
transcripts described above to this species is difficult with-
out further study, since SHBG has multiple glycoslyation
sites that could increase its observed size by up to 6 kilo-
daltons, and a 29 amino acid long signal peptide at its
amino terminus that may or may not be retained. Poten-
tial candidates include the 1L transcript lacking exons 6
and 7 which encodes an unmodified protein of 28.02
kilodaltons. If it exists, the exon 1L transcript lacking exon
4 encodes an unmodified protein of 37.87 kilodaltons;
without the signal peptide it would have a molecular
weight of 34.55 kilodaltons. Further studies should iden-
tify the origin of this novel smaller species. Compared to
HepG2 and LNCaP, the appearance of multiple larger spe-
cies in MCF-7 is likely due to differential glycosylation of
SHBG itself [33,46].
Discussion
It is evident from these results that the current view of
human SHBG gene structure, transcription, and, perhaps,
protein expression requires modification. In addition to
the two previously described human SHBG gene promot-
ers, PL, and PT, we provide evidence for a novel, third
upstream promoter, PN. Combined, these three promoters
are responsible for generating at least 19 unique tran-
scripts (Figure 9). To our knowledge, 15 of these 19 SHBG
gene transcripts are novel, with the smaller sized SHBG
mRNAs resulting from alternative splicing patterns that
target exons 4, 5, 6, and/or 7.
Alternative splicing of human SHBG transcripts
Certain nonannotated data in earlier studies on human
SHBG gene expression are consistent with the existence of
some of the novel, alternatively spliced human SHBG
transcripts in this communication. Using an identical
exon 5–8 RT-PCR assay, an uncharacterized small RT-PCR
fragment was generated from ZR-75-1 and MDA-MB-231
cells (Fig. 1 in [17]), whose molecular size is consistent
with the 176-bp fragment lacking exons 6 and 7 in our
exon 5–8 RT-PCR assay (Figure 2A). This fragment is also
Relative SHBG Gene Expression (Total and Promoter-specific) Among Human Cancer Cell Lines and Normal Tissues Figure 7
Relative SHBG Gene Expression (Total and Promoter-specific) Among Human Cancer Cell Lines and Normal 
Tissues. Quantitative RT-PCR (qPCR) was performed on total cellular RNA samples isolated from the indicated cell lines (in 
triplicate) and from normal tissues (in duplicate), using primers specific for SHBG exons 1L and 2, 1T and 2, 1N and 2, or exons 
2 and 3 as described in the Experimental Procedures. Each sample was analyzed by qPCR in triplicate (nine total measurements 
for each cell line per assay, six for each tissue). Ct values represent the number of cycles required to reach an arbitrary point 
on the exponential part of the qPCR curves. "Normalized Ct" values for each of the 1L-2, 1T-2, 1N-2 and 2–3 assays represent 
mean Ct values for a given sample, normalized to the mean GAPDH Ct value for that same sample. SD: Standard deviation, cal-
culated from the averages of the total measurements. Relative transcript abundance is presented as the ratio of Ct means; an 
arbitrary value of 1 is assigned to MCF-7.
31
Assay HepG2  MCF-7 LNCaP Prostate Testis  Liver  Breast 
GAPDH qPCR  Ct  16.09 16.04  16.65 18.81 19.24 21.49  17.42 
SD 0.11 0.08  0.69 0.04 0.06 0.15  0.07 
         
1L-2 qPCR  Normalized Ct  10.09 18.86  15.60 14.95 10.72 4.930  14.82 
SD 0.24 1.02  1.06 0.86 0.24 0.28  0.15 
         
1T-2 qPCR  Normalized Ct  18.82 20.83  13.52 15.83 6.370 13.73  17.20 
SD 0.69 0.67  1.27 0.63 0.10 0.52  0.61 
         
1N-2 qPCR  Normalized Ct  20.92 17.31  13.82 14.84 16.95 28.51  16.81 
 SD  0.90 0.53  1.52 0.51 0.83 0.15  0.45 
         
2-3 qPCR  Normalized Ct  10.61 15.67  12.35 12.67  6.66  5.63  12.55 
SD 0.31 0.31  1.11 0.42 0.21 0.30  0.20
         
         
 Assay:           
1L-2  438 1  9.59  15.1  282  15600  16.5
1T-2 4.04 1 158  32.1  2260  137  12.4 
1N-2 0.0810 1  11.2 5.52 1.28  0.000420 1.42 
Fold expression 
difference- 
normalized to MCF-7 
(2
(MCF7Ct-sampleCt)) 2-3 33.5  1  9.99 7.97 516 1060 8.74 BMC Molecular Biology 2009, 10:37 http://www.biomedcentral.com/1471-2199/10/37
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present in our MCF-7 assay but was not apparent in theirs.
Forges et al. (Figs. 2A and 2B in [47]) showed that human
testis expresses the four earlier described SHBG tran-
scripts; their data also include minor RT-PCR fragments
that correspond to novel transcripts characterized in the
present study. Selva et al. appear to generate at least one
faint intermediate band between the contiguous exon 1T-
8 and the exon 7 lacking RT-PCR fragments in human tes-
tis and sperm in their exon 1T-8 assay (Fig. 2B in [26]).
More recently, Ng et al. used an exon 3–7 RT-PCR assay to
demonstrate splicing of exon 4 alone [40]. In view of this
new profile of human SHBG transcription and alternative
splicing, conclusions from prior studies on SHBG expres-
sion based upon short-range RT-PCR assays may require
reevaluation.
Expression of the SHBG/ABP transcript
The notion that SHBG protein itself is expressed in certain
hormonally responsive tissues is supported by the tran-
scriptional profiles presented in this study, and our West-
ern blot results. Human prostate [19] and breast [16], and
specific regions of the brain [39] have previously been
shown to display immunoreactive SHBG protein. Our 1L-
8 RT-PCR assay showed that each of these tissues expresses
the SHBG/ABP transcript. Compared to liver, the relative
low expression of the transcript encoding SHBG in breast
and prostate is consistent with a local effect/need for
SHBG in acting on RSHBG. Extending this speculation,
fibulin-1D and fibulin-2 have been shown to sequester
plasma SHBG in the uterine stromal cells of transgenic
mice, with a preference for steroid-bound SHBG [48].
Such an interaction could be envisioned as regulating
local RSHBG signaling and/or sex steroid delivery in the
human prostate, where SHBG expression predominates in
luminal epithelial cells and RSHBG activity is highest in
stromal cells [49].
It has been recently reported that SHBG acts to actively
transport steroids into cells by binding of the endocytic
receptor, megalin [50], though this finding has been dis-
puted [51]. Should megalin serve such a function in the
breast and prostate, then locally expressed SHBG could be
a major player in steroid uptake in these tissues. Intracel-
lular SHBG might also bind specific sex steroids, thereby
influencing AR or ER activation. Therefore, locally
expressed SHBG could play a role in a number of different
biologic functions related to sex steroids.
Biologic significance of alternatively spliced SHBG gene 
transcripts
We suspect that only specific transcripts derived from PL
are likely candidates to encode stably translated SHBG
isoforms. The exon 8 reading frame is retained in PL
derived transcripts that lack exon 4 alone, exons 6 and 7,
and exons 4, 6, and 7. The remaining PL derived tran-
scripts, which present frameshifts within exon 8, appear
less likely to be stably translated; an E326 SNP variant of
SHBG, possessing a premature termination codon, is rap-
idly degraded [52] suggesting that motifs encoded within
exon 8 confer protein stability [35]. We do not rule out the
possibility that the exon 1L-8 transcript lacking exon 4
exists and went undetected due to aberrantly comigrating
sequences, considering that we detected an exon 1N-8
transcript that lacks exon 4 from a mixture of comigrating
RT-PCR fragments. Supporting this contention is a prior
report that showed HepG2 transcripts to undergo splicing
of exon 4 alone [40]. Based on its size alone, the 1L-8 tran-
script lacking exon 4 could encode the smaller, immuno-
reactive species recently described in human sperm [34].
Based upon their sequences, conventional translational
initiation events can not explain how human PN- or PT-
derived transcripts are translated into stable SHBG iso-
Western blot analysis of SHBG protein expression in  HepG2, LNCaP, and MCF-7 cells Figure 8
Western blot analysis of SHBG protein expression in 
HepG2, LNCaP, and MCF-7 cells. Protein extracts (20 
μg each) prepared from HepG2, LNCaP, and MCF-7 cells, 
and 10 picograms of purified SHBG protein isolated from 
human plasma using a steroid affinity column, were electro-
phoresed through 10% LongLife polyacrylamide gels (Gradi-
pore-VWR), transferred to PVDF membranes, and 
hybridized to either a rabbit anti-human SHBG polyclonal 
antibody (top, WAK-S1012-53, WAK-Chemie, Germany) or 
a rabbit anti-actin affinity purified polyclonal antibody (bot-
tom, A2066, Sigma). Molecular weight (in kilodaltons) 
marker positions are given on the left. The top band in 
HepG2 and LNCaP cells migrates with a molecular weight of 
approximately 44–46 kD, while the bottom band migrates 
with a molecular weight of approximately 33–35 kD. The 
two larger bands in MCF-7 migrate with molecular weights of 
51–53 kD and 48–50 kD, respectively. Note- the size marker 
appears to have run a bit slowly on the top gel, as the puri-
fied SHBG is slightly smaller than prior reports of 50–52 kD.
50kDa 
42
SHBG  MCF-7
-actin 
20
25
37
LNCaP HepG2 BMC Molecular Biology 2009, 10:37 http://www.biomedcentral.com/1471-2199/10/37
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forms. The first potential AUG start codon within exon 1N
heads a short, four amino acid open reading frame. The
subsequent AUG codon lies at the beginning of a 32
amino acid open reading frame; a termination codon pre-
cludes its merge into the exon 2 SHBG/ABP reading frame.
Exon 1T is devoid of an AUG start codon, the first poten-
tial AUG start codon within exon 2 of PT- derived tran-
scripts occurs at the beginning of a short open reading
frame consisting of only 10 amino acids. For such tran-
scripts, it has been suggested that translation may initiate
The human SHBG gene locus on chromosome 17p13.1 and its transcriptional expression Figure 9
The human SHBG gene locus on chromosome 17p13.1 and its transcriptional expression. Top: Exon structures of 
the SHBG gene and its neighboring genes are given as vertical lines. Transcriptional polarity is denoted by arrows. The polarity 
(designated by arrows) of the SHBG gene is opposite that of the SAT2 and FXR2 genes. SHBG upstream exon 1T abuts the 
SAT2 gene, and exon 1N is located within intron 1 of the FXR2 gene. Note the close proximity of the p53 gene. Bottom: An 
expanded structure of the human SHBG gene, showing the three SHBG gene promoters, PL, PT, and PN, the three first exons, 
1L, 1T, and 1N, and downstream exons 2–8. Numbers refer to relative positions along chromosome 17. Below is a representa-
tion of the structures of the 19 known human SHBG gene transcripts (boxes represent exons). Transcript structures are given 
on the right. Those representing the two major transcripts (SHBG/ABP and SHBG-T) and two minor transcripts (1L-8 lacking 
exon 7, and 1T-8) from prior reports are underlined. Alternative splicing of exon 4 from 1L-8 and 1T-8 transcripts was not spe-
cifically detected; these putative transcripts are presented in parentheses.BMC Molecular Biology 2009, 10:37 http://www.biomedcentral.com/1471-2199/10/37
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within exon 2 at a downstream AUG codon that shares the
SHBG/ABP open reading frame, or that they may utilize
alternative, rare start codons within exon 1T [34]. We note
that, beginning with the CUG at position +13, there are
eight possible alternative CUG, UUG, GUG, or AUA start
codons [53] within the long exon 1T open reading frame
that merges with the SHBG/ABP reading frame in exon 2.
More work is required to determine the biologic fates of
transcripts originating from PT and PN. Functionally, as
has been seen with other genes [54], it is feasible that non-
translated transcripts originating from PT and PN could be
regulatory in nature, affecting the expression of those that
do encode SHBG and stable SHBG isoforms.
The 1L-8 transcripts lacking exons 6 and 7 or exon 4 alone
could encode the smaller SHBG species we detected in
HepG2, LNCaP and MCF-7 cells. A similar sized species
was not identified in affinity purified SHBG from human
plasma, hence, it might not bind steroids, and/or it may
remain intracellular. The existence of an intracellular
SHBG species that does not bind steroid, but retains the
RSHBG membrane-binding motif within exon 3 [31] would
be quite exciting, as it could potentially affect RSHBG sign-
aling, as well as other SHBG mediated properties.
In addition to our finding of a smaller SHBG species in
cell lines, human hypothalamus and cerebrospinal fluid
have been shown to contain an immunoreactive SHBG
species which is 4.3-kD smaller than that of serum SHBG
[38]. Lower molecular weight species have been isolated
from human male genital tissue and myocardium [55,56].
Taken together, these results suggest that a deeper investi-
gation of alternatively spliced transcripts originating from
PL may explain these findings.
Human SHBG gene structure
The existence of human SHBG gene transcripts originating
from PT and PN fits a larger picture in which the mamma-
lian SHBG gene is in a state of evolutionary flux, 'hijack-
ing' promoter elements from adjacent upstream genes on
chromosome 17p13.1 that are transcribed in the opposite
orientation (Figure 9). PT, which is located 1.4 kb
upstream of PL, shares regulatory elements with the adja-
cent polyamine N-acetyltransferase (SAT2, NM_133491)
gene. Based on chromosomal mapping of SHBG exon 1N,
PN is located within intron 1 of the FXR2 gene. Such over-
lapping transcriptional units and bi-directional promoter
arrangements have been described for a number of genes;
computational studies of gene organization predict them
to occur frequently within the human genome [57,58].
The rat possesses homologous exon 1N sequences (Figure
5A), but these have not been reported in mature rat SHBG
transcripts. While prior work suggested that certain
orthologous sequences might be incorporated into
mature human transcripts, using RACE assays, we did not
specifically detect the existence of a human homologue of
rat PA [41,42]. Furthermore, the putative human exon 1A
region contains no potential start codons (Figure 5B),
thus, transcripts originating from a human PA would run
into the same functional and translational questions as do
transcripts derived from PT.
Relative abundance of human SHBG transcripts in tissues 
and cell lines
Transcripts derived from PL, PT, and PN are expressed dif-
ferentially in normal prostate, breast, liver, and testis. The
relative expression of the SHBG/ABP transcript is consist-
ent with our hypothesis regarding local generation of
SHBG vs. the utilization of plasma SHBG- that immedi-
ate, rapid effects of SHBG, including those mediated by
the RSHBG signaling pathway, are likely to be regulated
through local expression of SHBG within responsive tis-
sues; the concentration and/or availability of plasma
SHBG is not responsive to SHBG needs in particular sites.
Each of the cell lines we examined had a reduced abun-
dance of total 1L transcripts as compared to their corre-
sponding normal tissues, and more specifically this was
the case for the SHBG/ABP transcript. Furthermore, the
cancer cell lines examined in these studies had a greater
overall abundance of alternatively spliced PL derived tran-
scripts than did their corresponding normal tissues. If
SHBG gene expression is indeed modulated in prostate
and breast cancer, this could alter their androgen and
estrogen responsiveness.
Conclusion
In conclusion, our findings provide a broad and detailed
picture of human SHBG transcript structure and expres-
sion. At the same time, they also raise many new and
important questions, including the viability of novel alter-
natively spliced transcripts, their functions in hormonally
responsive tissues, including the breast and prostate, and
the role that aberrant SHBG gene expression may play in
cancer.
Methods
Cell lines
The LNCaP FGC, MCF-7 and HepG2 cell lines were pur-
chased from ATCC (Rockville, MD). LNCaP cells were
maintained in RPMI 1640 (10-0410CV, Mediatech, Hern-
don, VA), supplemented with 10% fetal bovine serum
(100–106, Gemini Bioproducts, West Sacramento, CA), 1
mM sodium pyruvate (Mediatech), 0.75% sodium bicar-
bonate (Mediatech), and 100 units/ml Penicillin-100 μg/
ml Streptomycin (GIBCO, Grand Island, NY). The clonal
MCF-7-Tr cell line, which constitutively expresses high
levels of a transcript containing the full length human
SHBG cDNA coding region, was generated by stably trans-
fecting MCF-7 cells with the plasmid, pCMV-FLAG-SHBG.
This plasmid contains the SHBG cDNA coding region
(NM_001040) cloned downstream of a CMV promoter,
and in frame with three iterations of an amino terminalBMC Molecular Biology 2009, 10:37 http://www.biomedcentral.com/1471-2199/10/37
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FLAG tag. MCF-7 and MCF-7-Tr cells were maintained in
DMEM (10-017-CV, Mediatech) supplemented with 10%
fetal bovine serum, 1 mM sodium pyruvate, 0.75%
sodium bicarbonate, 10 μM nonessential amino acids
(Mediatech) and 100 units/ml Penicillin-100 μg/ml
Streptomycin. HepG2 cells were grown in DMEM (10-
010-CV, Mediatech) supplemented with 10% fetal bovine
serum, 1 mM sodium pyruvate, 0.1 mM nonessential
amino acids, 0.75% sodium bicarbonate and 100 units/
ml Penicillin-100 μg/ml Streptomycin. Cells were refed
every 2–3 days and split 1:3 to 1:5 upon attaining ≥80%
confluence.
RNAs
Total cellular RNAs were isolated from exponentially
growing LNCaP, MCF-7, MCF-7-Tr, and HepG2 cells
using TRIzol reagent (Invitrogen, Carlsbad, CA), accord-
ing to the manufacturer's protocol. Total cellular RNAs
were purchased from Ambion, Inc. (FirstChoice Total
RNA; Applied Biosystems, Foster City, CA), these had
been isolated from pooled normal testes (AM7972), liver
(AM7960), prostate (AM7988), breast (AM6952), or
brain (AM7962) tissues and DNase treated.
Reverse Transcription-PCR (RT-PCR)
cDNA templates were generated using the cDNA cycle kit
(Invitrogen) or Superscript III kit (Invitrogen), according
to the manufacturer's protocol. One-two μg of RNA tem-
plate were used in a total volume of 50 μl, containing 2.5
units of Platinum Taq polymerase (Invitrogen), 1× Plati-
num Taq buffer, 200 nM of each PCR primer, and 1–3 μl
of cDNA. The primers used for PCR (Gene Link, Haw-
thorne, NY and MWG, Highpoint, NC) are presented [see
Additional file 1]. PCR amplifications were performed
using a denaturation step, 94°C for 10 minutes; followed
by 35 cycles of denaturation at 94°C for 30 seconds,
annealing (exon 5–8 assay: 54°C; exon 2–8 assay and
exon 1N-8 assay: 56°C; exon 1L-8 assay and 1T-8 assay:
57°C) for 1 minute, and extension at 72°C for 2 minutes,
followed by a final incubation at 72°C for 10 minutes.
PCR products were analyzed by gel electrophoresis as
before [19].
Rapid Amplification of cDNA Ends (RACE)
RNA Ligase Mediated (RLM)-RACE was performed using
the First Choice RLM-RACE kit (Ambion), according to
the manufacturer's protocol. This kit is designed to
amplify cDNA only from full-length, capped mRNA. Ten
μg of total RNA from LNCaP, MCF-7, HepG2, and normal
testis were used separately as starting material in standard
reactions. The supplied 5' RACE adapter used for ligation
to enzymatically decapped full length RNAs was: 5'-
GCUGAUGGCGAUGAAUGAACACUGCGUUUGCUG-
GCUUUGAUGAAA-3'
Outer 5'RLM-RACE PCR was performed using the sup-
plied 5'RACE outer primer and the SHBG exon 3 based
gene specific outer primer, SHBG Reverse RACE Exon 3
[see Additional file 1]. Inner 5' RLM-RACE PCR was per-
formed using the supplied 5'RACE inner primer and the
SHBG exon 2 based gene specific inner primer, SHBG
Reverse RACE Exon 2 [see Additional file 1]. RLM-RACE
products were analyzed as above.
DNA Sequencing
RT-PCR and RACE bands were stabbed with a sterile
pipette tip, and transferred into 50 μl of 1× Platinum Taq
buffer (Invitrogen); DNA fragments were eluted by 3
rounds of freeze-thawing. Five μl of each eluate were
reamplified using original PCR conditions. Ten μl aliq-
uots of each reamplified sample were analyzed by gel elec-
trophoresis, and appropriate sized bands were cut out and
eluted using the QIA quick gel extraction kit (Qiagen,
Valencia, CA). Sequencing was performed at the Colum-
bia University DNA Facility or at Genewiz Labs (Plain-
field, NJ); both DNA strands were sequenced using the
original PCR primers, and if necessary, nested primers.
Quantitative RT-PCR (qPCR)
Total cellular RNAs were isolated from triplicate plates of
exponentially growing HepG2, MCF-7 and LNCaP cells,
treated with RNase-free DNase (Qiagen), and aliquots
were analyzed by qPCR [59]. Duplicate aliquots of liver,
testis, prostate, and breast RNAs were similarly tested.
RNA aliquots were reverse transcribed to yield first-strand
cDNAs using the Applied Biosystems Reverse Transcrip-
tion Reagents protocol (Applied Biosystems) and prod-
ucts were diluted 1:10 in distilled H2O. Taqman assay
PCR reactions (Perkin-Elmer-Applied Biosystems) were
performed in triplicate in 96-well optical plates that
included appropriate negative control reactions and wells,
and run in an ABI PRISM 7700 Sequence Detection Sys-
tem machine. Assay-on-Demand Gene Expression Prod-
ucts (Applied Biosystems) were used; for individual
reactions, 2.5 μl of each sample were combined with 12.5
μl of 2× Taqman Universal Master Mix, 1.25 μl of Target
Assay Mix and 8.75 μl H2O. Predesigned Taqman assays
for SHBG exons 2–3, 1L-2, and 1T-2 (Hs01050181_g1;
Hs01050180_g1; and Hs01050186_m1) were purchased
from Applied Biosystems. Assay by design primers
(Applied Biosystems) SHBG exon 1N-1NF (forward
primer), SHBG exon 1N-1NR (reverse primer), and SHBG
exon 1N-1NM2 (probe) were used [see Additional file 1].
Data were extracted and amplification plots generated
with ABI SDS software. Threshold cycle (Ct) scores, which
represent the cycle number at which fluorescence signal
crosses an arbitrary (user-defined) threshold, were aver-
aged for subsequent calculations of relative expressionBMC Molecular Biology 2009, 10:37 http://www.biomedcentral.com/1471-2199/10/37
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values. For each of the four individual SHBG qPCR assays:
1) exon 2–3; 2) exon 1L-2; 3) exon 1T-2; and 4) exon 1N-
2, and for each individual cell line and tissue, mean SHBG
Ct scores were normalized against mean Ct scores for the
endogenous control gene, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), and standard deviations were
calculated. Expression ratios for each assay were deter-
mined relative to MCF-7 expression by the following cal-
culation: Relative Expression = 2-ΔCt  where  ΔCt =
normalized sample Ct – normalized MCF-7 Ct.
Western Blot Analysis
HepG2, LNCaP, and MCF-7 cells were grown in 100 cm2
dishes until they were approximately 80% confluent. After
rinsing cells twice with cold PBS, two mls of protein
extraction buffer (50 nM Tris Ph 8.0, 0.15 M NaCl, 0.5%
NP40, 1× Halt Protease Inhibitor cocktail (#78430,
Thermo Scientific)) were added to each plate, and left o/n
on a shaker at 4°C. Cellular suspensions were collected
and microfuged at 11,000 × g for 15 minutes at 4°C.
Supernatants containing solubilized protein were trans-
ferred to sterile tubes, and protein concentrations were
determined by Bradford assay (Biorad).
Equal amounts of protein (20 ug) from each cell line were
loaded onto precast 10% LongLife gels (NH21-010, Grad-
ipore-VWR), along with 10 pg of purified SHBG protein
isolated from human plasma. Gel electrophoresis was per-
formed at 75 volts in Tris-HEPES-SDS running buffer. Pro-
tein transfer onto PVDF membranes was performed at 15
volts for 30 minutes in an SD Transblot Cell (Biorad),
using 25 mM Tris-base (pH 7.4), 192 mM Glycine, in 15%
methanol as transfer buffer.
PVDF membranes were blocked by incubating overnight
at 4°C in 20 mls of SuperBlock blocking buffer (Pierce
Biotechnology, Rockford, IL) in Tris-buffered saline (pH
7.4) containing 0.5% Tween-20 (TBST) with gentle shak-
ing. Membranes were then washed three times for five
minutes each with 20 mls of SuperBlock Blocking Buffer/
TBST with gentle shaking. Next, membranes were covered
with 10 mls of SuperBlock Blocking Buffer/TBST contain-
ing a 1/1000 dilution of either a rabbit anti-hSHBG anti-
body (WAK-S1012-53, WAK-Chemie, Germany) or a
rabbit anti-actin antibody (A2066, Sigma). Primary anti-
body incubation was for one hr at room temperature with
gentle shaking, after which membranes were washed as
above and covered with 10 mls of SuperBlock Blocking
Buffer/TBST containing a 1/2000 dilution of Goat Anti-
Rabbit IgG(H+L) conjugated to horseradish peroxidase
(Cat. No. 31460, Pierce Biotechnology). Incubation with
the secondary antibody was for one hr at room tempera-
ture with gentle shaking, after which membranes were
washed as above, equilibrated in PBS, processed with
Western Blotting Luminol Reagent (Cat. No. SC-2048,
Santa Cruz Biotechnology, Santa Cruz, CA), and exposed
to x-ray film.
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